title: Renal function and venous thromboembolic diseases.
abstract: Anticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agents in CKD patients because of the pharmacokinetic modifications of these drugs in this population. These modifications may lead to overdosage and dose-related side effects, such as bleeding. It is therefore necessary to screen VTE patients for CKD and to modify the doses of anticoagulants, if necessary.
authors.affiliation: Service ICAR, Pitié-Salpêtrière university hospital, 83, boulevard de l'Hôpital, 75013 Paris, France; Department of nephrology, Pitié-Salpêtrière hospital, 75013 Paris, France. Electronic address: nicolas.janus@aphp.fr.
authors.forename: N
authors.initials: N
authors.lastname: Janus
authors.affiliation: Internal medicine department, Louis-Mourier hospital, 92701 Colombes, France.
authors.forename: I
authors.initials: I
authors.lastname: Mahé
authors.affiliation: Service ICAR, Pitié-Salpêtrière university hospital, 83, boulevard de l'Hôpital, 75013 Paris, France; Department of nephrology, Pitié-Salpêtrière hospital, 75013 Paris, France.
authors.forename: V
authors.initials: V
authors.lastname: Launay-Vacher
authors.affiliation: Vascular medicine department, Saint-Eloi hospital, 34000 Montpellier, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Laroche
authors.affiliation: Service ICAR, Pitié-Salpêtrière university hospital, 83, boulevard de l'Hôpital, 75013 Paris, France; Department of nephrology, Pitié-Salpêtrière hospital, 75013 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Deray
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002318:Cardiovascular Diseases; D062787:Drug Overdose / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000503:physiopathology*; D011655:Pulmonary Embolism; D051436:Renal Insufficiency, Chronic / Q000150:complications / Q000503:physiopathology; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K; D006493:Heparin
keywords: Anticoagulants; Anticoagulants agents; Chronic kidney disease; Insuffisance rénale chronique; Maladie thrombo-embolique veineuse; Venous thromboembolism